| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $14.5M | -8.7% |
| SG&A Expense | $9.7M | -56.2% |
| Operating Income | -$24.2M | +36.4% |
| Income Tax | $0 | -100.0% |
| Net Income | -$13.7M | +60.1% |
| EPS (Basic) | -$1.22 | +84.1% |
| EPS (Diluted) | -$1.22 | +84.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $7.9M | +43.5% |
| Short-term Investments | $10.7M | +88.1% |
| Current Assets | $19.7M | +69.5% |
| Total Assets | $19.8M | +62.4% |
| Current Liabilities | $3.7M | -8.5% |
| Total Liabilities | $5.4M | +33.7% |
| Stockholders' Equity | $14.4M | +76.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$21.1M | +17.8% |
| Capital Expenditures | $8K | -89.7% |
| Investing Cash Flow | -$4.4M | -149.8% |
| Financing Cash Flow | $28.0M | +33.8% |
| Free Cash Flow | -$21.2M | +18.0% |